CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields（EFE-P100） Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05661240
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:52.233707+00:00
Published At: 2022-12-22T00:00:00+00:00
Record Updated At: 2022-12-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-small Cell Lung Cancer (NSCLC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-12-22"
protocolSection.identificationModule.nctId: "NCT05661240"
protocolSection.identificationModule.officialTitle: "Phase \u2161/\u2162 Clinical Study of Tumor Treating Fields\uff08EFE-P100\uff09 Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.